Rep. Katie Porter Destroys Pharma CEO Over His Insane Bonuses

Representative Katie Porter gave one of the best arguments for price controls on pharmaceuticals that we've seen in a long time this week when she completely eviscerated a drug company CEO over the price of just one of their drugs. Porter tied the argument to the bonus received by the CEO, and even had a white board where she showed very clearly and concisely why the arguments for the big bonuses and price hikes were absolutely ridiculous. Ring of Fire's Farron Cousins discusses this.

Become a member today!

Support us by becoming a monthly patron on Patreon, and help keep progressive media alive!

Find our merchandise at Teespring

Spread the word! LIKE and SHARE this video or leave a comment to help direct attention to the stories that matter. And SUBSCRIBE to stay connected with Ring of Fire's video content!

Support Ring of Fire by subscribing to our YouTube channel

Be sociable! Follow us on:

Follow more of our stories at

Subscribe to our podcast

*This transcript was generated by a third-party transcription software company, so please excuse any typos.

Yesterday in the house of representatives, there was a hearing, uh, with current and former pharmaceutical executives about the exorbitant cost of medications here in the United States and representative Katie Porter gave a, I don't know if you'd call it questioning or if you call it testimony, or if you just call it a flat out lesson in what happens to the price of these drugs and how it correlates to the bonuses received by the CEO's, uh, Porter representative Porter was talking to former, uh, Selgin CEO, Mark owls. And this is what happened during that exchange. This was absolutely beautiful. Take a look.

Do you know what this number is? Aye. Does it ring any bells?

I think you're referring to my compensation in some way.

You'll in some way, this was your compensation in 2017 for being CEO of Celgene. And that's a lot of money. It's 200 times the average American's income and 360 times what the average senior gets on a social security. Now of that 13 million, about 2.1 million came from your company hitting yearly earning targets. Um, and more than half of the bonus formula was based on those targets. Any increase in the price of Revlamid would also increase your bonus by increasing earnings. Isn't that right? Mr. Ellis,

If revenues increased and expensive and did not then earnings, wouldn't be enhanced.

Thank you, mr. Alison from the oversight committee found that if you hadn't increased the price of Revlamid, you wouldn't have gotten your bonus. Mr. Ellis, do you know how much you personally received in bonuses over two years? The last two years, just because Celgene raised the price of this one drug Revlamid.

I received very generous compensation, but I don't know the exact number that you're referring to.

In fact, you personally received half of a half, a million dollars personally, just by tripling the price of Revlimid. So to recap here, the drug didn't get any better. The cancer patients didn't get any better. You just got better at making money. You just refined your skills at price gouging. And to be clear, the taxpayer spent 3.3 billion and Revlimid.

I love this point that she is bringing up because we have seen members of the squad. In fact, yesterday, uh, members of the squad, uh, AOC to leap Presley all would after CEO's as well. And they've done it the past. They've talked about, you know, the R and D costs, but this, what, what, what representative Porter did here was slightly different. And another good point to bring up to kind of, you know, round out the bigger picture. And that is the pay, the pay that the, the CEOs are taking in because it's not just the profits of the company itself. It's not just the constant markups of drugs that the R and D was paid off for 20 years ago. Because by the way, it takes fewer than two years for a drug company to recoup the entire cost of research and development for a drug.

After that, it's all profits and marketing and let's not forget, they didn't even pay for most of the R and D. So technically that's all profit. They get back to cause that's the government paid for it. They just get to keep it. And they count it as we recouping the cost. But the CEOs, these are the people that call the shots, the people that have control over all of this, they could change it. They could stop it.